On the other hand, mice carrying the deacetylation mimetic of PPARγ (K268R/K293R, 2KR) retain the insulin-sensitizing effects of TZD but not the adverse side effects including bone loss, fluid retention, and heart hypertrophy when treated with the TZD drug rosiglitazone (Rosi) and are protected against diet-induced or aging-associated obesity (Kraakman et al., 2018). This evidence concerns the gene PPARG and obesity disorder.